Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies

References

• World Health Organization. WHO Coronavirus(COVID 19) Dashboard. 2023 Oct 21. https://covid19.who.int/.
   Google Scholar
• Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, Haag E, Zeller M, Aceves CM, Zaiets K, et al. Outbreak.Info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. 2023.
   Google Scholar
• Telenti A, Hodcroft EB, Robertson DL. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12(5):a041390. doi:10.1101/cshperspect.a041390.
   PubMed Web of Science ®Google Scholar
• Jenni P, Shanron S, Patricia J, Judy O. Kuby immunology. 8thed. W. H. Freeman; 25 May 2018.
   Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, Ferbas KG, Tobin NH, Aldrovandi GM, Yang OO. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020;383(11):1085–8. doi:10.1056/NEJMc2025179.
   PubMed Web of Science ®Google Scholar
• Elliott P, Bodinier B, Eales O, Wang H. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science. 2022 Mar 25;375(6587):1406–1411. doi:10.1126/science.abn8347.
   Web of Science ®Google Scholar
• McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, Wu P, Leung GM, Cowling BJ. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–43. doi:10.1016/S1473-3099(22)00345-0.
   PubMed Web of Science ®Google Scholar
• Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, Amit S, Jaber H, Doolman R, Asraf K, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol. 2022;23(6):940–6. doi:10.1038/s41590-022-01212-3.
   PubMed Web of Science ®Google Scholar
• Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, Epsi NJ, Fries AC, Agan BK, Lindholm DA, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 2022;14(645):eabn8543. doi:10.1126/scitranslmed.abn8543.
   PubMed Web of Science ®Google Scholar
• Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, Smith ZR, Miller J, Verani JR, Schrag SJ. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. JAMA. 2022;327(22):2210. doi:10.1001/jama.2022.7493.
   PubMed Web of Science ®Google Scholar
• Humoral and cellular immune memory to four COVID-19 vaccines. 33.
   Google Scholar
• Jung MK, Jeong SD, Noh JY, Kim D-U, Jung S, Song JY, Jeong HW, Park S-H, Shin E-C. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. Nat microbiol. 2022;7(6):909–17. doi:10.1038/s41564-022-01123-x.
   PubMed Web of Science ®Google Scholar
• Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–41. doi:10.1016/S1473-3099(22)00271-7.
   PubMed Web of Science ®Google Scholar
• Maringer Y, Nelde A, Schroeder SM, Schuhmacher J, Hörber S, Peter A, Karbach J, Jäger E, Walz JS. Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci Immunol. 2022;7(78):eadd3899. doi:10.1126/sciimmunol.add3899.
   PubMed Web of Science ®Google Scholar
• Wesemann - 2022 - Omicron’s message on vaccines boosting begets bre.Pdf.
   Google Scholar
• Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, Bednarski E, Ramos V, Zong S, Johnson B, et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128–34. doi:10.1038/s41586-022-04778-y.
   PubMed Web of Science ®Google Scholar
• Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, Mathew D, Pattekar A, Reynaldi A, Khoury DS, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022;185(11):1875–87.e8. doi:10.1016/j.cell.2022.04.009.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang R, Qiao S, Wang X, Zhang W, Ruan W, Dai L, Han P, Gao GF. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. 2022;387(3):277–80. doi:10.1056/NEJMc2206900.
   PubMed Web of Science ®Google Scholar
• Shaw RH, Liu X, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respir Med. 2022;10(11):1049–60. doi:10.1016/S2213-2600(22)00163-1.
   PubMed Web of Science ®Google Scholar
• Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(8):e2228008. doi:10.1001/jamanetworkopen.2022.28008.
   PubMed Web of Science ®Google Scholar
• Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance, 16 December 2021. 2021.
   Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CB, De la Cruz E, Jorge A, De los Santos M, et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience. 2021. http://medrxiv.org/lookup/doi/10.1101/2021.12.27.21268459.
   Google Scholar
• Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Sci. 2021;371(6534):1152–3. doi:10.1126/science.abg6105.
   PubMed Web of Science ®Google Scholar
• Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, et al. Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant. 2022. http://medrxiv.org/lookup/doi/10.1101/2022.01.04.22268755.
   Google Scholar
• Lu C, Zhang Y, Liu X, Hou F, Cai R, Yu Z, Liu F, Yang G, Ding J, Xu J, et al. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. 30.
   Google Scholar
• Li J-X, Wu S-P, Guo X-L, Tang R, Huang B-Y, Chen X-Q, Chen Y, Hou L-H, Liu J-X, Zhong J, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10(8):739–48. doi:10.1016/S2213-2600(22)00087-X.
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, Pan H, Wang X, Song Z, Wan J, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–9. doi:10.1038/s41591-021-01677-z.
   PubMed Web of Science ®Google Scholar
• Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, Wu Y, Behl S, Taylor JJ, Chakaraborty R, et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022;7(76):eadd4853. doi:10.1126/sciimmunol.add4853.
   PubMed Web of Science ®Google Scholar
• Mao T, Israelow B, Peña-Hernández MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022;378(6622):eabo2523. doi:10.1126/science.abo2523.
   PubMed Web of Science ®Google Scholar
• Yao L, Zhu K-L, Jiang X-L, Wang X-J, Zhan B-D, Gao H-X, Geng X-Y, Duan L-J, Dai E-H, Ma M-J. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis. 2022;22(8):1116–17. doi:10.1016/S1473-3099(22)00410-8.
   PubMed Web of Science ®Google Scholar
• Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Krüger K, Wallisch A-K, Adams-Quack P, Bacher M, Finlayson A, et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022;7(75):eabq2427. doi:10.1126/sciimmunol.abq2427.
   PubMed Web of Science ®Google Scholar
• Kaku CI, Bergeron AJ, Ahlm C, Normark J, Sakharkar M, Forsell MNE, Walker LM. Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. Sci Immunol. 2022;7(73):eabq3511. doi:10.1126/sciimmunol.abq3511.
   PubMed Web of Science ®Google Scholar
• Koutsakos M, Lee WS, Reynaldi A, Tan H-X, Gare G, Kinsella P, Liew KC, Taiaroa G, Williamson DA, Kent HE, et al. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity. 2022;55(7):1316–26.e4. doi:10.1016/j.immuni.2022.05.018.
   PubMed Web of Science ®Google Scholar
• Minervina AA, Pogorelyy MV, Kirk AM, Crawford JC, Allen EK, Chou C-H, Mettelman RC, Allison KJ, Lin C-Y, Brice DC, et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat Immunol. 2022;23(5):781–90. doi:10.1038/s41590-022-01184-4.
   PubMed Web of Science ®Google Scholar
• Fraser R, Orta-Resendiz A, Mazein A, Dockrell DH. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends Mol Med. 2023;29(4):255–67. doi:10.1016/j.molmed.2023.01.003.
   PubMed Web of Science ®Google Scholar
• Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity. 2022;55(5):749–80. doi:10.1016/j.immuni.2022.04.013.
   PubMed Web of Science ®Google Scholar